Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label Phase I dose-escalation study of oral venetoclax in combination with
increasing cytarabine doses plus mitoxantrone to define the safety profile and MTD of
cytarabine in subjects with a histologically or cytologically confirmed acute myeloid
leukemia who are refractory or suffered a relapse. This study will be conducted at multiple
centers in Germany.